This project develops novel inhaled antibacterial prototypes for multidrug-resistant pulmonary diseases, including tuberculosis, nontuberculous mycobacterial infections, and Gram-negative pathogens such as Pseudomonas aeruginosa. The PI with over 15 years of experience in antibacterial design will synthesize about 20-30 new derivatives using click-chemistry, based on cinnamamide, para-aminosalicylic acid, and hydroxy(aza)naphthanilide scaffolds with proven in-vitro activity. Inhalation delivery is chosen to maximize local lung exposure while reducing systemic toxicity, overcoming the limits of oral antibiotics. In partnership with the University of Vienna, candidates will undergo profiling (solubility, pKa/logP, cytotoxicity, permeability, epithelial retention) in Calu-3 models. The project will advance from TRL 2–3 to TRL 5, delivering validated sterile solutions for nebulization and paving the way for next-generation therapies with strong clinical and commercial potential.

Sustainable Development Goals

Masaryk University is committed to the UN Sustainable Development Goals, which aim to improve the conditions and quality of life on our planet by 2030.